Fennec Pharms Inc Drug Patent Portfolio
Fennec Pharms Inc owns 1 orange book drug protected by 7 US patents Given below is the list of Fennec Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11291728 | Anhydrous sodium thiosulfate and formulations thereof | 01 Jul, 2039 | Active |
| US11510984 | Anhydrous sodium thiosulfate and formulations thereof | 01 Jul, 2039 | Active |
| US11617793 | Anhydrous sodium thiosulfate and formulations thereof | 01 Jul, 2039 | Active |
| US11964018 | Therapeutic uses for sodium thiosulfate formulations | 01 Jul, 2039 | Active |
| US11992530 | Therapeutic uses for sodium thiosulfate and formulations | 01 Jul, 2039 | Active |
| US11998604 | Therapeutic uses for sodium thiosulfate formulations | 01 Jul, 2039 | Active |
| US10596190 | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy | 05 Jan, 2038 | Active |
Latest Legal Activities on Fennec Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Fennec Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eCofC Notification | 16 Jul, 2024 | US11617793 |
|
Email Notification
Critical
| 16 Jul, 2024 | US11617793 |
| Patent eCofC Notification | 16 Jul, 2024 | US11617793 |
| Recordation of Patent eCertificate of Correction | 16 Jul, 2024 | US11617793 |
| Mail Certificate of Correction Memo | 30 May, 2024 | US11291728 |
| Certificate of Correction Memo | 29 May, 2024 | US11291728 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Apr, 2024 | US11964018 |
| Mail Patent eGrant Notification | 23 Apr, 2024 | US11964018 |
|
Email Notification
Critical
| 23 Apr, 2024 | US11964018 |
| Recordation of Patent eGrant | 23 Apr, 2024 | US11964018 |
| Patent eGrant Notification | 23 Apr, 2024 | US11964018 |
|
Recordation of Patent Grant Mailed
Critical
| 23 Apr, 2024 | US11964018 |
| Mail Patent eCofC Notification | 09 Apr, 2024 | US11510984 |
| Recordation of Patent eCertificate of Correction | 09 Apr, 2024 | US11510984 |
| Patent eCofC Notification | 09 Apr, 2024 | US11510984 |
Fennec Pharms Inc's Drug Patent Litigations
Fennec Pharms Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 29, 2021, against patent number US10596190. The petitioner Hope Medical Enterprises, Inc., challenged the validity of this patent, with Oregon Health & Science University et al. as the respondent. Click below to track the latest information on how companies are challenging Fennec Pharms Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10596190 | October, 2021 |
Final Written Decision
(18 Apr, 2023)
| Oregon Health & Science University et al. | Hope Medical Enterprises, Inc. |
Fennec Pharms Inc's Family Patents
Fennec Pharms Inc Drug List
Given below is the complete list of Fennec Pharms Inc's drugs and the patents protecting them.
1. Pedmark
Pedmark is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11291728 | Anhydrous sodium thiosulfate and formulations thereof |
01 Jul, 2039
(14 years from now)
| Active |
| US11510984 | Anhydrous sodium thiosulfate and formulations thereof |
01 Jul, 2039
(14 years from now)
| Active |
| US11617793 | Anhydrous sodium thiosulfate and formulations thereof |
01 Jul, 2039
(14 years from now)
| Active |
| US11964018 | Therapeutic uses for sodium thiosulfate formulations |
01 Jul, 2039
(14 years from now)
| Active |
| US11992530 | Therapeutic uses for sodium thiosulfate and formulations |
01 Jul, 2039
(14 years from now)
| Active |
| US11998604 | Therapeutic uses for sodium thiosulfate formulations |
01 Jul, 2039
(14 years from now)
| Active |
| US10596190 | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
05 Jan, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pedmark's drug page